AdventHealth Research Featured in Circulation Research Compendium

On July 10, 2025, AdventHealth Director of Neuroscience Clinical Research Anita Fletcher, MD, worked with NKGen Biotech to administer the first dose of troculeucel (SNK01), an investigative natural...

In our latest Clinician’s View, Dr. Seminerio shares her personal passion for improving care for patients with inflammatory bowel disease (IBD) and talks about how AdventHealth’s recently established...

Under the leadership of Principal Investigator Valeria Baldivieso, MD, and Sub-Investigator Chandan Reddy, MD, MS, FAANS, the AdventHealth Research Institute is recruiting patients for the Exablate...

New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative...

For people with Type 1 diabetes (T1D), low blood sugar episodes—also known as hypoglycemia—can strike fast and hard. The body’s natural defense is to release hormones like glucagon to raise blood...

A new study reveals that people newly diagnosed with Type 2 diabetes face a significantly higher risk of developing aggressive cancers—including those of the liver, pancreas, and colon.

Dr. Richard Pratley, Samuel E. Crockett Chair in Diabetes Research and Medical Director of AdventHealth Diabetes Institute, recently shared insights with Healio Endocrinology about the importance of...

Under the leadership of principal investigator Michael Seidman, MD, AdventHealth Research Institute is participating in the multi-site Clinical Trial of Etanercept (TNF-alpha Blocker) for Treatment of...

Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...